Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.

Mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes are reported in acute myeloid leukemia (AML). We studied the frequency and the clinicopathologic features of IDH1 and IDH2 mutations in AML. Mutations in IDH1 (IDH1(R)¹³²) and IDH2 (IDH2(R)¹⁷²) were assessed by Sanger sequencing in 199 AML cases. Point mutations in IDH1(R)¹³² were detected in 12 (6.0%) of 199 cases and in IDH2(R)¹⁷² in 4 (2.0%) of 196 cases. Of the 16 mutated cases, 15 (94%) were cytogenetically normal, for an overall frequency in this group of 11.8%. IDH1(R)¹³² and IDH2(R)¹⁷² mutations were mutually exclusive. Concurrent mutations in NPM1, FLT3, CEBPA, and NRAS were detected only in AML with the IDH1(R)¹³² mutation. The clinical and laboratory variables of patients with AML with IDH mutations showed no significant differences compared with patients with wild-type IDH. We conclude that IDH1(R)¹³² and IDH2(R)¹⁷² mutations occur most often in cytogenetically normal AML cases with an overall frequency of approximately 11.8%.

[1]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Döhner,et al.  Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. , 2008, Seminars in oncology.

[3]  O. Abdel-Wahab,et al.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.

[4]  S. Scholl,et al.  Clinical implications of molecular genetic aberrations in acute myeloid leukemia , 2009, Journal of Cancer Research and Clinical Oncology.

[5]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[6]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[7]  A. Marchetti,et al.  IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.

[8]  N. Yoo,et al.  Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers , 2009, International journal of cancer.

[9]  F. Ferrara,et al.  Clinically useful prognostic factors in acute myeloid leukemia. , 2008, Critical reviews in oncology/hematology.

[10]  A. Green,et al.  Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. , 2010, The New England journal of medicine.

[11]  D. Birnbaum,et al.  Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.

[12]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[13]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[14]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[15]  V. Velculescu,et al.  Mutant metabolic enzymes are at the origin of gliomas. , 2009, Cancer research.

[16]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[17]  L. Medeiros,et al.  Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. , 2006, American journal of clinical pathology.

[18]  H. Mikawa,et al.  Metabolic basis for differential glutamine requirements of human leukemia cell lines , 1990, Journal of cellular physiology.

[19]  S. Serrano,et al.  KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations , 2008, Modern Pathology.

[20]  M. Fey,et al.  Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype , 2005, Clinical Cancer Research.

[21]  K. Wagner,et al.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[23]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[24]  C. Hoogenraad,et al.  Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma , 2010, Human mutation.

[25]  A. Aventín,et al.  A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. , 2006, Haematologica.

[26]  E. Gottlieb,et al.  IDH1 mutations in gliomas: when an enzyme loses its grip. , 2010, Cancer cell.

[27]  H. Koeppen,et al.  Application of COLD-PCR for improved detection of KRAS mutations in clinical samples , 2009, Modern Pathology.

[28]  I. Bernstein,et al.  Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study , 2010, Leukemia.

[29]  Tak W. Mak,et al.  Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.

[30]  C. Thompson,et al.  Metabolic enzymes as oncogenes or tumor suppressors. , 2009, The New England journal of medicine.

[31]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[32]  K. Döhner,et al.  Impact of new prognostic markers in treatment decisions in acute myeloid leukemia , 2009, Current opinion in hematology.

[33]  J. Weinberg,et al.  Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin. , 1989, Blood.

[34]  C. Bloomfield,et al.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.

[35]  L. Medeiros,et al.  t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. , 2004, American journal of clinical pathology.

[36]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[37]  Jih-Luh Tang,et al.  Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. , 2010, Blood.

[38]  Guido Marcucci,et al.  Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics , 2005, Current opinion in hematology.

[39]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.